<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2682</journal-id><journal-id journal-id-type="pmc-domain">cas</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11158325</article-id><article-id pub-id-type="pmcid-ver">PMC11158325.1</article-id><article-id pub-id-type="pmcaid">11158325</article-id><article-id pub-id-type="pmcaiid">11158325</article-id><article-id pub-id-type="pmid">19068085</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.2008.01023.x</article-id><article-id pub-id-type="publisher-id">CAS1023</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Experimental Therapeutics and Clinical Medicine</subject></subj-group></subj-group></article-categories><title-group><article-title>Phase I study of TZT&#8208;1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3&#160;weeks</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author" corresp="yes"><name name-style="western"><surname>Yamamoto</surname><given-names initials="N">Nobuyuki</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="a2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name name-style="western"><surname>Andoh</surname><given-names initials="M">Masahiro</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr3" contrib-type="author"><name name-style="western"><surname>Kawahara</surname><given-names initials="M">Masaaki</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr4" contrib-type="author"><name name-style="western"><surname>Fukuoka</surname><given-names initials="M">Masahiro</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr5" contrib-type="author"><name name-style="western"><surname>Niitani</surname><given-names initials="H">Hisanobu</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="a1">
<label>
<sup>1</sup>
</label>TZT&#8208;1027 Cooperative Study Group;</aff><aff id="a2">
<label>
<sup>2</sup>
</label>Division of Thoracic Oncology, Shizuoka Cancer Center. Shimonagakubo 1007 Shunto&#8208;gun, Shizuoka 411&#8208;8777, Japan</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
To whom correspondence should be addressed. E&#8208;mail: <email>n.yamamoto@scchr.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2009</year></pub-date><volume>100</volume><issue seq="18">2</issue><issue-id pub-id-type="pmc-issue-id">464474</issue-id><issue-id pub-id-type="doi">10.1111/cas.2009.100.issue-2</issue-id><fpage>316</fpage><lpage>321</lpage><history>
(Received July 23, 2008/Revised September 19, 2008/Accepted October 6, 2008/Online publication December 8, 2008)</history><pub-history><event event-type="pmc-release"><date><day>08</day><month>12</month><year>2008</year></date></event><event event-type="pmc-live"><date><day>08</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-08 10:25:16.983"><day>08</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2008 Japanese Cancer Association</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAS-100-316.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAS-100-316.pdf"/><abstract><p>TZT&#8208;1027 is a novel synthetic dolastatin 10 derivative that inhibits tubulin polymerization. A phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT&#8208;1027, and to assess its pharmacokinetic profile in Japanese patients with advanced solid tumors following administration of the drug weekly for 3&#160;weeks. Eligible patients had advanced solid tumors that failed to respond to standard therapy or for which no standard therapy was available, and met the following criteria: performance status&#160;&#8804;2 and acceptable organ function. The MTD was defined as the highest dose at which more than two&#8208;thirds of the patients experienced grade 4 hematological toxicity or grade 3/4 non&#8208;hematological toxicity during weekly TZT&#8208;1027 administration for 3&#160;weeks. Forty patients were enrolled in the present study. Twelve doses between 0.3 and 2.1&#160;mg/m<sup>2</sup> were evaluated. Grade 4 neutropenia was the principal dose&#8208;limiting toxicity (DLT). At a dose of 2.1&#160;mg/m<sup>2</sup>, two patients developed DLT: one patient developed grade 4 neutropenia, grade 3 myalgia, and grade 4 constipation, and the other one developed grade 4 neutropenia and grade 3 constipation. At a dose level of 1.8&#160;mg/m<sup>2</sup>, toxicity was acceptable and no DLT was observed. The area under the curve and maximum concentration of TZT&#8208;1027 tended to increase linearly with the dose. The DLT observed were neutropenia, myalgia, and constipation, and the MTD was 2.1&#160;mg/m<sup>2</sup>. The recommended dose for a phase II study was determined to be 1.8&#160;mg/m<sup>2</sup> for the drug administered weekly for 3&#160;weeks. (<italic toggle="yes">Cancer Sci</italic> 2009; 100: 316&#8211;321)</p></abstract><counts><fig-count count="2"/><table-count count="5"/><equation-count count="0"/><ref-count count="22"/><page-count count="6"/><word-count count="3985"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2009</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.4 mode:remove_FC converted:05.06.2024</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>